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Oxidative stress is not associated 
with vascular dysfunction in a model 
of alloxan-induced diabetic rats
Estresse oxidativo não está associado à disfunção vascular 
em um modelo de diabetes induzida por aloxana em ratos
Verena Kise Capellini1, Caroline Floreoto Baldo1, Andréa Carla Celotto1, 
Marcelo Eduardo Batalhão2, Evelin Capellari Cárnio2, Alfredo José Rodrigues1, 
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ABSTRACT
Objectives: To verify if an experimental model of alloxan-diabetic rats promotes oxidative 
stress, reduces nitric oxide bioavailability and causes vascular dysfunction, and to evaluate 
the effect of N-acetylcysteine (NAC) on these parameters. Methods: Alloxan-diabetic rats were 
treated or not with NAC for four weeks. Plasmatic levels of malondialdehyde (MDA) and nitrite/
nitrate (NOx), the endothelial and inducible nitric oxide synthase (eNOS and iNOS) immunos-
taining and the vascular reactivity of aorta were compared among diabetic (D), treated diabetic 
(TD) and control (C) rats. Results: MDA levels increased in D and TD. NOx levels did not differ 
among groups. Endothelial eNOS immunostaining reduced and adventitial iNOS increased in 
D and TD. The responsiveness of rings to acetylcholine, sodium nitroprusside, and phenylephri-
ne did not differ among groups. Conclusions: NAC had no effect on the evaluated parameters 
and this experimental model did not promote vascular dysfunction despite the development of 
oxidative stress. Arq Bras Endocrinol Metab. 2010;54(6):530-9
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RESUMO 
Objetivos: Verificar se um modelo experimental de diabetes por aloxana promove estresse 
oxidativo, reduz a disponibilidade de óxido nítrico e causa disfunção vascular, e avaliar o efeito 
da N-acetilcisteína (NAC) nesses parâmetros. Métodos: Ratos diabéticos por aloxana foram 
tratados com NAC por quatro semanas. Níveis plasmáticos de malondialdeído (MDA) e nitrito/
nitrato (NOx), imunomarcação para óxido nítrico sintase endotelial e induzida (eNOS e iNOS) e 
reatividade vascular da aorta foram comparados entre ratos diabéticos (D), diabéticos tratados 
(TD) e controles (C). Resultados: O MDA aumentou nos grupos D e TD. O NOx não diferiu entre 
os grupos. A marcação da eNOS no endotélio reduziu e a da iNOS na adventícia aumentou nos 
grupos D e TD. A responsividade dos anéis vasculares à acetilcolina, nitroprussiato de sódio e 
fenilefrina não diferiu entre os grupos. Conclusões: A NAC não teve efeito sobre os parâmetros 
avaliados. Esse modelo experimental não promoveu disfunção vascular apesar do desenvolvi-
mento de estresse oxidativo. Arq Bras Endocrinol Metab. 2010;54(6):530-9
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INTRODUCTION
Vascular diseases are the main causes of death and disability in people with diabetes (1). Oxidative 
stress is the ultimate cause of structural and functional 
changes to vascular cells in diabetic patients, and the 
superoxide anion (•O2
-) is responsible for the reduced 
nitric oxide (NO) bioavailability (2). The reaction be-
tween •O2
- and NO forms peroxynitrite (ONOO-) (3), 
which is able to promote lipid peroxidation (4). More-
over, ONOO- can oxidize tetrahydrobiopterin (BH4), 
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Oxidative stress in diabetic rats
leading to a phenomenon known as “nitric oxide syn-
thase (NOS) uncoupling”, which in turn results in •O2
- 
synthesis instead of NO production by NOS (5).
Despite the overwhelming evidence of decreased 
NO bioavailability in diabetes (3,6), investigations re-
garding vascular reactivity exhibit quite conflicting re-
sults, thereby jeopardizing the exact participation of 
NO in diabetic dysfunctions. There are many reports 
showing impaired endothelium-dependent relaxation 
(7-10), while others demonstrate unaltered (11-13) 
and even augmented endothelium-dependent rela-
xation (14,15). Vascular reactivity experiments also 
provided controversial results when the endothelium-
independent relaxation and the contraction responses 
of the smooth muscle were evaluated (8,10,12,16-19). 
These conflicting data prompted us to investigate 
whether an experimental model of alloxan-diabetic rats 
promotes oxidative stress, reduces NO bioavailability, 
and causes vascular dysfunction. The effects of treat-
ment with N-acetylcysteine (NAC) on the same va-
riables were also examined. NAC, an antioxidant and 
glutathione precursor, was the drug of choice due to 
its wide capacity of attenuating oxidative stress in many 
diseases (20,21). 
METHODS
Animals and induction of diabetes
Male Wistar rats (200-210 g) were housed on a 12h 
light-dark cycle, under constant temperature (22oC), 
and were allowed free access to standard laboratory diet 
and drinking water. The investigation was approved by 
the Ethical Animal Committee of the University of São 
Paulo, Campus of Ribeirão Preto. 
Diabetes was induced by a single intravenous tail vein 
injection of alloxan (40 mg/kg; Sigma, St. Louis, MO, 
USA) after a 24h fast with water ad libitum. Alloxan was 
freshly dissolved in 50 µL of sodium citrate (0.05 M, 
pH 4.5) immediately before use. An equivalent volume 
of citrate was administered by the same route to control 
animals. The rats were considered diabetic if they had 
glycemia ≥ 200 mg/dL at 7 days after alloxan injection. 
Blood glucose levels were determined using a glucome-
ter and glucose test strips (Precision Plus Electrodes, Me-
disense Products, Bedford, USA) following a 12h fast.
Experimental design
The animals were randomly assigned to three groups 
(n = 10 each): control (C), diabetic (D), and treated 
diabetic (TD). NAC (Deg, São Paulo, Brazil) was ad-
ministered to the TD group in the drinking water for 4 
weeks. NAC was freshly dissolved in drinking water, to 
give a daily intake of 1.4 g/kg body weight (22) (avera-
ge 1.270 ± 0.202 g/kg/day). The experimentation pe-
riod was ended by anesthetizing the rats with thiopental 
sodium (40 mg/kg, intraperitoneal injection; Cristália, 
São Paulo, Brazil), laparotomy was then performed for 
blood sampling from the abdominal aorta. Finally, the 
animal was exsanguinated via abdominal aorta and tho-
racotomy was performed for thoracic aorta harvesting. 
Glycemia and body weight measurements
Fasting blood glucose (determined as previously descri-
bed) and body weight were measured immediately be-
fore alloxan injection, at 1 week after alloxan injection 
(when the diabetes was confirmed and the animals were 
randomly assigned to diabetic groups), and at 5 weeks 
after alloxan injection (end of the treatment period).
Plasma malondialdehyde measurement
Arterial blood samples were collected in tubes contai-
ning EDTA. After blood centrifugation (3000×g, 10 
min, 4°C), plasma aliquots were removed and stored at 
−70°C until analysis. Plasma malondialdehyde (MDA) 
concentration was measured using a commercially avai-
lable kit (Lipid Peroxidation Assay kit, Calbiochem, San 
Diego, CA, USA). The assay is based on the ability of a 
chromogenic agent to react with MDA, yielding a sta-
ble chromophore with maximal absorbance at 586 nm.
Plasma nitrite and nitrate levels
Arterial blood samples were collected in tubes contai-
ning heparin. After blood centrifugation (3000×g, 10 
min, 4°C), plasma aliquots were removed and stored at 
−70°C. Samples were analyzed in duplicates for nitrite 
and nitrate (NOx) using an ozone-based chemilumi-
nescence assay. Briefly, the plasma samples were treated 
with cold ethanol (1 volume of plasma: 2 volumes of 
ethanol for 30 min at −20°C) and centrifuged (4000×g, 
10 min). NOx levels were measured by injecting 25 μL 
of the supernatant in a glass purge vessel containing 
0.8% of Vanadium (III) in HCl (1 N) at 90°C, which 
reduces NOx to NO gas. A nitrogen stream was bub-
bled through the purge vessel containing Vanadium 
(III), then through NaOH (1 N), and then into an 
NO analyzer (Sievers® Nitric Oxide Analyzer 280, GE 
Analytical Instruments, Boulder, CO, USA).
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Immunohistochemical assay for endothelial and 
inducible nitric oxide synthases
Thoracic aortic samples were immediately fixed in 10% 
buffered formalin solution for 24h and embedded in 
paraffin. Paraffin-embedded tissue blocks were sectio-
ned at 3 µm. The sections were processed for endothe-
lial nitric oxide synthase (eNOS) and inducible nitric 
oxide synthase (iNOS) staining using a commercially 
available kit (DAKO LSAB®2 Kit, Peroxidase for use on 
RAT Specimens, DAKO Corporation, Carpinteria, CA, 
USA). In brief, the sections were fixed to slides pre-
treated with [3-aminopropyl]triethoxysilane (Sigma, 
St. Louis, MO, USA). Subsequently, the sections were 
deparaffinized and rehydrated through a descending al-
cohol series followed by distilled water. In sequence, 
the endogenous peroxidase activity was inactivated with 
hydrogen peroxide, and the sections were incubated 
with citrate buffer in a humidified heat chamber (Op-
tisteam Plus, Krups North America Inc., New Jersey, 
USA) for antigen retrieval. The non-specific bindings 
were blocked with swine normal serum. The sections 
were incubated with polyclonal eNOS antibody (NOS3 
(H-159): sc-8311, Santa Cruz Biotechnology, Califor-
nia, USA) at a dilution of 1:25 or monoclonal iNOS an-
tibody (NOS2 (C-11): sc-7271, Santa Cruz Biotechno-
logy, California, USA) at a dilution of 1:5. In sequence, 
the sections were incubated with secondary antibody of 
LSAB®2 kit and then with the streptavidin peroxidase 
of the same kit. Finally, the reactions were revealed with 
3,3’-diaminobenzidine tetrahydrochloride (Sigma, St. 
Louis, MO, USA), and the sections were counterstai-
ned with Harris’ haematoxylin. As negative controls, 
sections were processed with the above procedures, but 
the primary or secondary antibodies were omitted.
All slides were observed and photographed with 
a high definition camera (AxioCam HRc, Zeiss, Ger-
many) coupled to a microscope (Axioskop 2 plus, 
Zeiss, Germany). The immunostaining was graduated 
in 4 classes (0 – when the tissue was not marked, as 
in negative controls, 1 – when the tissue was marked 
lightly, 2 − when the tissue was marked moderately, and 
3 − when the tissue was marked densely) by an observer 
blind to the animal group. 
Morphometric analysis of the thoracic aorta medial 
layer
Thoracic aorta samples were immediately fixed in 10% 
buffered formalin solution for 24h and embedded in 
paraffin. Paraffin-embedded tissue blocks were sectio-
ned at 3 µm, and sections were stained with Masson’s 
trichrome. With the use of a high definition camera 
(AxioCam HRc, Zeiss, Germany) coupled to a micros-
cope (Axioskop 2 plus, Zeiss, Germany), all slides were 
photographed in such a way that the vascular ring fitted 
a unique image. The area and the mean thickness of 
the thoracic aorta muscular layer were measured by an 
observer unaware of the animal group by means of the 
KS400 – Carl Zeiss version 2.0. To obtain the area of 
the muscular layer, each vascular ring was submitted to 
manual exclusion of the adventitia and perivascular tis-
sues by the use of the “eraser” tool after zooming in. In 
sequence, the mean thickness of the muscular layer was 
obtained by choosing the lines (vertical, horizontal, or 
radial) that best fitted the vascular ring according to its 
orientation on the slide. 
Vessel preparation and isometric tension recording
The thoracic aorta was carefully dissected free of con-
nective tissue and immersed in a cooled and oxygena-
ted Krebs solution (NaCl: 118.0, KCl: 4.7, CaCl2: 2.5, 
KH2PO4: 1.2, MgSO4: 1.66, glucose: 11.1, NaHCO3: 
25.0 (mM), pH 7.4). Ring segments of the thoracic 
aorta (4 mm in length) were prepared with great care, 
so as not to touch the intimal surface. In some seg-
ments the endothelium was removed by gently rubbing 
the intimal surface of the blood vessel with a pair of 
watchmaker’s forceps. This procedure removes endo-
thelium but does not affect the ability of the vascular 
smooth muscle to contract or relax.
Thoracic aorta segments were mounted in organ 
chambers (10 mL) filled with Krebs solution maintained 
at 37°C and bubbled with 95% O2/5% CO2 (pH 7.4). 
Each arterial ring was suspended by two stainless steel 
clips placed through the lumen. One clip was anchored 
to the bottom of the organ chamber, while the other 
was connected to a strain gauge for measurement of the 
isometric force using Grass FT03 (Grass Instrument 
Company, Quincy, MA, USA). The rings were placed at 
an optimal length-tension of 1.5 g (10,12) and allowed 
to equilibrate for 60 minutes with the bath fluid being 
changed every 15 to 20 minutes. Endothelial integri-
ty was assessed qualitatively by the degree of relaxation 
caused by acetylcholine (Ach, 10-6 M; Sigma, St. Louis, 
MO, USA) in the presence of contractile tone induced 
by phenylephrine (Phe, 10-7 M; Sigma, St. Louis, MO, 
USA). For studies of endothelium intact vessels, the 
ring was discarded if relaxation with Ach was not 80% 
or greater. For studies of endothelium-denuded vessels, 
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rings were discarded if there was any measurable degree 
of relaxation. Sequentially, each ring was washed and re-
equilibrated for 30 min. Aortic rings were then precon-
tracted with Phe (10-7 M), and cumulative concentra-
tion-response curves were obtained after a stable plateau 
was reached. The endothelium-dependent relaxation 
was evoked by Ach (10-10 - 10-5 M) in intact aortic rin-
gs, while the endothelium-independent vasorelaxation 
was evoked by sodium nitroprusside (SNP, 10-10 - 10-5 M; 
Sigma, St. Louis, MO, USA) in denuded rings. Cumulati-
ve concentration-response curves for Phe (10-10 - 10-5 M) 
were determined on endothelium-intact and -denuded 
aortic rings. Concentration-response curves were also 
accomplished by pre-incubating the vascular rings with 
Nω-nitro-L-arginine methyl ester (L-NAME, 10-4 M, 
a non-specific NOS inhibitor; Calbiochem, San Diego, 
CA, USA) for 50 minutes. 
Statistical analysis
Statistical two-way repeated-measures ANOVA and 
Bonferroni post-test data evaluations were performed 
using the program SPSS 15.0 (Apache Software Foun-
dation, 2000). Values were considered to be statistically 
significant at p values less than 0.05.
RESULTS
Glycemia and body weight
The initial glycemia and body weight did not differ 
among the groups. After the alloxan injection, diabetic 
and treated diabetic rats presented higher fasting blood 
glucose and lower body weight than control animals 
(p < 0.001). NAC treatment did not affect glycemia or 
body weight compared with diabetic animals without 
treatment (Table 1).
Plasma MDA and NOx levels
At the end of the 4-week treatment, plasma MDA levels 
were significantly higher in diabetic (p = 0.003) and trea-
ted diabetic animals (p = 0.015) than those in the control 
group. At the end of the same period, plasma NOx levels 
did not differ among the groups. Administration of NAC 
did not change plasma MDA or NOx levels compared 
with diabetic rats without treatment (Table 2).
eNOS and iNOS immunohistochemical analysis 
The intensity of positive eNOS immunostaining de-
creased in the thoracic aorta endothelium of diabetic 
and treated diabetic rats compared with age-matched 
control rats (p = 0.007). However, NAC treatment did 
not affect the eNOS immunostaining in the endothe-
lium. In the muscular layer, the eNOS immunostaining 
ranged from light to moderate and there were no diffe-
rences among the three groups. In the adventitia, no 
positive immunostaining for eNOS was observed in any 
group (Table 3, Figure 1A).
In the endothelial and smooth muscle layers of thora-
cic aorta, the iNOS immunostaining was not evident in 
any group. However, the intensity of positive iNOS im-
munostaining increased in the adventitia of diabetic and 
treated diabetic rats compared with their age-matched 
control rats (p < 0.001). Again, NAC treatment did not 
affect the iNOS immunostaining (Table 3, Figure 1B). 
Thoracic aorta muscular layer area and mean thickness 
The area of the thoracic aorta smooth muscle of dia-
betic and treated diabetic animals decreased compared 
with control (p = 0.001 and p < 0.001, respectively). 
Moreover, NAC treatment promoted a reduction in the 
area of aorta medial layer of treated diabetic compared 
with non-treated diabetic rats (p = 0.029) (Table 4).
Table 1. Fasting blood glucose and body weight in control, diabetic and treated diabetic rats
Control Diabetic Treated diabetic 
Fasting glucose (mg/dL) Day of alloxan injection 92.60 ± 8.87 90.10 ± 8.99 87.40 ± 16.15
1 week after alloxan injection 90.10 ± 8.99 364.47 ± 53.18* 352.33 ± 56.94*
5 weeks after alloxan injection 85.27 ± 8.73 435.83 ± 53.00* 401.67 ± 54.28*
Body   weight (g) Day of alloxan injection 190.70 ± 16.81 199.80 ± 11.99 198.36 ± 6.45
1 week after alloxan injection 312.60 ± 20.66 216.42 ± 36.97* 200.39 ± 26.73*
5 weeks after alloxan injection 514.71 ± 24.72 220.21 ± 67.97* 205.54 ± 42.52*
Values were obtained previous and after alloxan-induced diabetes in diabetic and treated diabetic rats or vehicle administration in control rats. All values are means ± SD (n = 10). * p < 0.001 vs. control 
(One-way ANOVA, Bonferroni’s Multiple Comparison Test).
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Table 2. Plasma MDA and NOx levels in control, diabetic and treated 
diabetic rats
Control Diabetic Treated  diabetic 
MDA (µM) 4.45 ± 1.57 8.71 ± 2.42* 9.44 ± 3.31#
NOx (µM) 30.28 ± 4.67 28.68 ± 11.06 48.55 ± 31.00
Values were obtained 5 weeks after alloxan-induced diabetes in diabetic and treated diabetic rats 
or vehicle administration in control rats. All values are means ± SD (n = 10). * p = 0.003 vs. 
control, # p = 0.015 vs. control (One-way ANOVA, Games-Howell’s Multiple Comparison Test).
Table 3. Degree of eNOS and iNOS immunostaining in the three layers of 
thoracic aorta of the control, diabetic and treated diabetic rats
Control Diabetic Treated diabetic 
Degree of eNOS 
immunostaining
endothelium 2.56 ± 0.53 1.61 ± 0.66* 1.64 ± 1.01*
muscle 1.78 ± 0.83 1.65 ± 0.65 1.50 ± 0.52
adventitia 0 0 0
Degree of iNOS 
immunostaining
endothelium 0 0 0
muscle 0 0 0
adventitia 0 3# 3#
The values were attributed according to immunostain intensity. All values are means ± SD 
(n = 10). * p = 0.007 vs. control, # p < 0.001 vs. control (Kruskal-Wallis Test).
Figure 1. Photomicrography of thoracic aorta of control, diabetic, and treated diabetic animals. A) Endothelial nitric oxide synthase (eNOS) immunostaining: 
note that the three vessel layers were stained; however; the eNOS immunostaining is decreased in the endothelium of diabetic rats, treated or not (scale bar 
= 100 µm). B) Inducible nitric oxide synthase (iNOS) immunostaining: observe that only the adventitia of diabetic and treated diabetic rats was stained (scale 
bar = 0.5 mm).
A) eNOS B) iNOS
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Table 4. Area and mean thickness of thoracic aorta muscular layer in 
control, diabetic and treated diabetic rats
Control Diabetic Treated diabetic 
Area (mm2) 2.48 ± 0.48 1.62 ± 0.18† 1.08 ± 0.50*#
Mean thickness (mm) 0.14 ± 0.02 0.09 ± 0.01* 0.09 ± 0.00*
All values are means ± SD (n = 10). † p = 0.001 vs. control, * p < 0.001 vs. control, # p = 0.029 vs. 
diabetic (One-way ANOVA, Games-Howell’s Multiple Comparison Test).
Oxidative stress in diabetic rats
The mean thickness of the thoracic aorta muscular 
layer was also lower in diabetic and treated diabetic ani-
mals compared with age-matched controls (p < 0.001). 
However, administration of NAC had no effect on the 
mean thickness when diabetic rats were compared with 
treated diabetic animals (Table 4).
Thoracic aorta vascular function 
In the relaxation study, changes in vascular wall ten-
sion were expressed as a percent of the relaxation of 
the maximal contraction following exposure to Phe, a 
convention that corrects inter-animal variability in the 
response of the tissue to the drug. 
In the contraction study, changes in vascular wall ten-
sion were expressed as g of tension/dry weight (mg) of 
the aorta ring that generates the respective curve. This 
convention avoids measurement errors that may arise 
from inter-animal variability to the amount of tissue.
Endothelium-dependent relaxation
Ach caused concentration-dependent relaxation of the 
endothelium-intact aortic rings of the 3 groups in the 
absence of any inhibitor (p < 0.001) (Figure 2A) and in 
the presence of L-NAME (C: p = 0.007; D: p = 0.001; 
TD: p < 0.001) (Figure 2B). 
In inter-group comparisons, no statistical differences 
were observed among groups when the concentration-
response curves were achieved without NOS inhibition 
(Figure 2A). However, after L-NAME incubation, the 
endothelium-intact rings of diabetic and treated dia-
betic rats relaxed more than the rings obtained from 
control animals (p = 0.020 and p = 0.025, respectively); 
moreover, there was no statistical difference between 
treated and non-treated diabetic animals (Figure 2B).
Endothelium-independent relaxation
SNP caused concentration-dependent relaxation of en-
dothelium-denuded aortic rings irrespective of group 
(p ≤ 0.001), with no inter-group statistical differences 
(Figure 3). 
Figure 2. Vasodilator responses of rat thoracic aorta segments of control, diabetic, and treated diabetic groups. Phenylephrine-preconstricted aorta rings 
with endothelium were relaxed with cumulative concentrations of acetylcholine in the absence (A) and in the presence of L-NAME (B). All values are means 
+ SD (n = 10). a p < 0.001 in within-group comparison; b p = 0.007 in within-group comparison; c p = 0.001 in within-group comparison; d statistical 
difference compared to control (C vs. D: p = 0.020 and C vs. TD: p = 0.025). Repeated measures two-way ANOVA, Greenhouse-Geisser Test (intra-group 
comparison), Games-Howell Test (inter-group comparison).
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Figure 3. Vasodilator responses of rat thoracic aorta segments of control, 
diabetic, and treated diabetic groups. Phenylephrine-preconstricted aorta 
rings without endothelium were relaxed with cumulative concentrations of 
sodium nitroprusside. All values are means + SD (n = 10).  a p ≤ 0.001 in 
within-group comparison. Repeated measures two-way ANOVA, 
Greenhouse-Geisser Test (intra-group comparison), Games-Howell Test 
(inter-group comparison).
Figure 4. Concentration-response curves for phenylephrine in rat thoracic aorta segments of control, diabetic, and treated diabetic groups. A) Concentration-
response curves were obtained from endothelium intact (full symbols) and denuded-rings (open symbols). B) Concentration-response curves were obtained 
from endothelium intact-rings before and after L-NAME incubation. All values are means + SD (n = 10). a p < 0.001 in within-group comparison. Repeated 
measures two-way ANOVA, Greenhouse-Geisser Test (intra-group comparison), Games-Howell Test (inter-group comparison).
Oxidative stress in diabetic rats
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Contraction study
Phe caused concentration-dependent contraction of 
denuded aortic rings (Figure 4A) and endothelium-
intact rings, pre-incubated or not with L-NAME (Fi-
gure 4B) irrespective of group (p < 0.001) and with no 
inter-group statistical differences (Figures 4A and 4B). 
DISCUSSION 
The alloxan-induced diabetes model in rats has been 
widely employed (23-26), and the present study rein-
forces the ability of this diabetogenic drug to promote 
experimental diabetes in rats since the animals presen-
ted hyperglycemia and reduced body weight, as obser-
ved by many authors (8,10,12,18).
As already mentioned, hyperglycemia induces oxi-
dative stress. This relationship has been demonstrated 
in many investigations, including our study. Increased 
levels of MDA or other biomarkers of oxidative stress 
have been observed in humans with type 1 (27) and 
type 2 diabetes (28) and in experimental models of type 
1 (12,18,25,29) and type 2 diabetes (16,30,31). Taking 
this into consideration, NAC treatment aiming at re-
duced MDA levels represents a promising therapeutic 
opportunity. But, in spite of many reports reassuring 
its beneficial effect on oxidative stress (22,32-34), our 
study has failed to reduce MDA concentrations. We do 
not have a clear understanding about the reason why 
NAC treatment did not restore normal MDA levels, 
but we hypothesize that this failure could be related to 
NAC dose or late onset of NAC treatment. However, 
lower doses of NAC normalized ROS production in 
streptozotocin-diabetic rats (35), and NAC treatment 
initiated one week after diabetes induction also nor-
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malized the plasma and tissue levels of oxidative stress 
markers in streptozotocin-diabetic rats (34). Thus, 
another hypothesis to explain NAC failure in this study 
would be the diabetogenic agent used here, since all 
researches reviewed by us demonstrated reduction in 
oxidative stress after NAC treatment when streptozo-
tocin was employed as a diabetogen. Furthermore, the 
activity of the γ-glutamylcysteine syntethase, the enzy-
me responsible for glutathione synthesis, was reduced 
in liver alloxan-diabetic rabbits, accounting for reduced 
glutathione concentrations (36). If this is so, reduced 
synthase activity may blunt the NAC antioxidant effect.
Increased oxidative stress is known to reduce NO 
bioavailability in diabetes (3,6). Indeed, researches that 
measure NO or its products and •O2
- in endothelial 
cell culture (37), vessels (16,30), or plasma (38) have 
demonstrated an inverse relationship between NO and 
ROS in hyperglycemic conditions. However, plasma 
NOx levels did not differ among groups in our study, 
despite the presence of enhanced plasma MDA concen-
trations in diabetic rats. One reasonable explanation for 
this apparent contradiction of normal NOx levels in the 
presence of increased oxidative stress in diabetic rats is 
the incomplete inactivation of NO by ROS. This hypo-
thesis is based on the inherent capacity of iNOS to pro-
duce greater amounts of NO (in the order of nanomols 
to micromols) (39) and on the fact that the aorta from 
our diabetic animals, treated or not, presented incre-
ased intensities of immunostaining for iNOS. There-
fore, despite a reduction in eNOS immunostaining in 
the endothelium from the aorta of diabetic rats, which 
was observed by other authors (40,41), the increase in 
iNOS immunostaining could have made sufficient NO 
available to exert its biological effects. These ideas were 
also defended by Bojunga and cols., who had similar 
results (42).
Another result that reinforces our suggestion that 
NO bioavailability was not reduced in diabetic animals 
is the normal response of endothelium-intact rings from 
these animals to Ach, even after NOS inhibition. We 
also verified that after L-NAME incubation the endo-
thelium-intact rings from diabetic rats, treated or not, 
presented a higher relaxing response to Ach than the 
control rings. However, we do not have sufficient data 
to affirm that this enhanced endothelium-dependent 
relaxation of the aorta from diabetic rats can be due to 
larger NO bioavailability, which was suggested as a pos-
sible vascular damaging agent in experimental diabetes 
(42). In addition, we cannot forget that other factors, 
such as the prostacyclin and the endothelium-derived 
hyperpolarizing factor can participate in relaxation. 
Our results also show that this model of diabetes 
does not induce vascular smooth muscle dysfunction, 
neither endothelium-independent relaxation nor con-
traction aortic capability presented alterations. Previous 
reports also demonstrated unchanged vascular smooth 
muscle responsiveness to NO and (nor)adrenergic ago-
nists in diabetic rings (10,12,43). Indeed, the investiga-
tions that observed enhanced vascular smooth muscle 
responsiveness to contracting agents related it to impai-
red endothelial NO synthesis during the evocation of 
a contraction (18,19). However, our graphs show that 
both NOS inhibition and endothelium removal resulted 
in the same effect: an increase in contracting response, 
leading to the supposition that NO availability was not 
impaired in this model of experimental diabetes. 
We also observed that the area and the mean thi-
ckness of the muscular layer of the aorta were decrea-
sed in diabetic rats, treated or not, which is compatible 
with the lower body weights of these animals and em-
phasizes the need for adopting a correction factor for 
concentration-response curve comparisons. The treated 
diabetic animals presented lower aortic smooth muscle 
area than non-treated diabetic rats, but we believe that 
this difference can be assumed as an artifact. This sug-
gestion is based on the fact that all vascular segments 
obtained from treated diabetic animals collapsed when 
immersed in formalin. However, the mechanism or the 
reaction that leads to this collapse is unknown.
The possible explanations given for the develop-
ment or not of vascular dysfunction in diabetes can be 
related to different glucose concentrations in the media 
during the vascular reactivity study (44), the duration 
of diabetes, the vascular bed (44-46), and the studied 
species (44,45). We credit the failure in the vascular 
dysfunction development of our model to insufficient 
diabetes duration, which was reinforced by a recent re-
port showing that diabetes lasting 4 weeks does not 
promote vascular dysfunction, whereas diabetes lasting 
8 weeks causes endothelium-dependent and indepen-
dent relaxation impairment (17).
CONCLUSION 
In summary, the experimental model of alloxan-induced 
diabetes in rats lasting 5 weeks is effective for the de-
velopment of diabetes and oxidative stress but fails to 
promote vascular dysfunction. NAC administration for 
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4 weeks to these diabetic animals does not reduce oxida-
tive stress, change NOx levels, or alter vascular function.
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